Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide in Nelson's Syndrome
2009-014457-33Phase 2Completed
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Oct 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in Nelson's syndrome, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoints: Effect of acute and chronic pasireotide on circulating ACTH levels and Effect of chronic pasireotide therapy on pituitary tumour volume. Started Oct 2010; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Nelson's syndrome
Beyond the preview
Go deeper on 2009-014457-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014457-33.